

# Tulisokibart (MK-7240) Clinical Trials Program

MSD is applying its expertise to the discovery and development of therapies to help address the unmet medical needs of patients with immune-mediated inflammatory diseases.

**Tulisokibart (MK-7240)** is an investigational humanized monoclonal antibody directed to a novel target, tumor necrosis factor (TNF)-like ligand 1A (TL1A), which is a proinflammatory and profibrotic cytokine associated with immune-mediated inflammatory diseases.

## Pivotal Phase 3 Clinical Trials

MSD is conducting multiple pivotal Phase 3 clinical trials to evaluate the efficacy and safety of tulisokibart in patients with the two main types of inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn's disease (CD).

Study Titles	Study Name
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants With Moderately to Severely Active Ulcerative Colitis	ATLAS-UC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Moderately to Severely Active Crohn's Disease	ARES-CD

In addition, there is an ongoing Phase 3 extension study, MK-7240-011, to evaluate the long-term efficacy and safety of tulisokibart in patients who participated in a previous tulisokibart study for UC or CD.

## Phase 2 Clinical Trials

MSD is also conducting Phase 2 clinical trials to evaluate the efficacy and safety of tulisokibart in patients with immune-mediated inflammatory diseases in rheumatology and dermatology, including hidradenitis suppurativa, radiographic axial spondyloarthritis (ankylosing spondylitis), rheumatoid arthritis and systemic sclerosis associated with interstitial lung disease (SSc-ILD).

Study Titles	Study Name
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Moderate to Severe Hidradenitis Suppurativa	MK-7240-012
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis)	MK-7240-013
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Rheumatoid Arthritis	MK-7240-014
A Phase 2 Safety and Efficacy Study of Tulisokibart in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD)	MK-7240-007